84 related articles for article (PubMed ID: 2630145)
1. [Tetrahydroisoquinoline and parkinsonism].
Yoshida M
Rinsho Shinkeigaku; 1989 Dec; 29(12):1501-3. PubMed ID: 2630145
[TBL] [Abstract][Full Text] [Related]
2. Parkinsonism produced by tetrahydroisoquinoline (TIQ) or the analogues.
Yoshida M; Ogawa M; Suzuki K; Nagatsu T
Adv Neurol; 1993; 60():207-11. PubMed ID: 8093578
[TBL] [Abstract][Full Text] [Related]
3. Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: the behavioral and biochemical changes.
Yoshida M; Niwa T; Nagatsu T
Neurosci Lett; 1990 Oct; 119(1):109-13. PubMed ID: 1982957
[TBL] [Abstract][Full Text] [Related]
4. An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions.
Nagatsu T; Yoshida M
Neurosci Lett; 1988 Apr; 87(1-2):178-82. PubMed ID: 2898112
[TBL] [Abstract][Full Text] [Related]
5. Migration of tetrahydroisoquinoline, a possible parkinsonian neurotoxin, into monkey brain from blood as proved by gas chromatography-mass spectrometry.
Niwa T; Takeda N; Tatematsu A; Matsuura S; Yoshida M; Nagatsu T
J Chromatogr; 1988 Oct; 452():85-91. PubMed ID: 3149649
[TBL] [Abstract][Full Text] [Related]
6. Antidopaminergic effects of 1,2,3,4-tetrahydroisoquinoline and salsolinol.
Antkiewicz-Michaluk L; Michaluk J; Romańska I; Papla I; Vetulani J
J Neural Transm (Vienna); 2000; 107(8-9):1009-19. PubMed ID: 11041279
[TBL] [Abstract][Full Text] [Related]
7. Effect of tetrahydroisoquinoline (TIQ), one of endogenous substances inducing parkinsonism, on isolated rat vas deferens.
Koike K; Takayanagi I; Wani S; Yanagita T; Ohta S; Hirobe M
Gen Pharmacol; 1989; 20(2):259-60. PubMed ID: 2714622
[TBL] [Abstract][Full Text] [Related]
8. Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys: effect of levodopa and GM1 ganglioside therapy.
Kastner A; Herrero MT; Hirsch EC; Guillen J; Luquin MR; Javoy-Agid F; Obeso JA; Agid Y
Ann Neurol; 1994 Aug; 36(2):206-14. PubMed ID: 7914399
[TBL] [Abstract][Full Text] [Related]
9. [The search for endogenous or exogenous MPTP-like substances].
Nagatsu T
Rinsho Shinkeigaku; 1989 Dec; 29(12):1497-500. PubMed ID: 2517047
[TBL] [Abstract][Full Text] [Related]
10. [Tetrahydroisoquinolines in connection with Parkinson's disease].
Ohta S
Rinsho Shinkeigaku; 1989 Dec; 29(12):1504-6. PubMed ID: 2698297
[TBL] [Abstract][Full Text] [Related]
11. Dystonia induced by combined treatment with L-dopa and MK-801 in parkinsonian monkeys.
Rupniak NM; Boyce S; Steventon MJ; Iversen SD; Marsden CD
Ann Neurol; 1992 Jul; 32(1):103-5. PubMed ID: 1642462
[TBL] [Abstract][Full Text] [Related]
12. Chronic administration of 1-benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous amine in the brain, induces parkinsonism in a primate.
Kotake Y; Yoshida M; Ogawa M; Tasaki Y; Hirobe M; Ohta S
Neurosci Lett; 1996 Oct; 217(1):69-71. PubMed ID: 8905742
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and brain accumulation of tetrahydroisoquinoline (TIQ) a possible parkinsonism inducing substance, in an animal model of a poor debrisoquine metabolizer.
Ohta S; Tachikawa O; Makino Y; Tasaki Y; Hirobe M
Life Sci; 1990; 46(8):599-605. PubMed ID: 2308469
[TBL] [Abstract][Full Text] [Related]
14. 1-Methyl-1,2,3,4-tetrahydroisoquinoline, decreasing in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse, prevents parkinsonism-like behavior abnormalities.
Tasaki Y; Makino Y; Ohta S; Hirobe M
J Neurochem; 1991 Dec; 57(6):1940-3. PubMed ID: 1940911
[TBL] [Abstract][Full Text] [Related]
15. No reduction of dopamine transporter binding sites in mice following treatment with the TIQ analogue 1-benzyl-1,2,3,4-tetrahydroisoquinoline.
Ishiwata K; Koyanagi Y; Abe K; Kawamura K; Taguchi K; Saitoh T; Toda J; Sano T
Brain Res; 2003 Jan; 960(1-2):282-5. PubMed ID: 12505685
[TBL] [Abstract][Full Text] [Related]
16. Dopaminergic antagonists: effects of 1,2,3,4-tetrahydroisoquinoline and its N-methyl and N-propyl homologs on apomorphine- and L-dopa-induced behavioral effects in rodents.
Ginos JZ; Doroski D
J Pharmacol Exp Ther; 1979 Apr; 209(1):79-86. PubMed ID: 571017
[TBL] [Abstract][Full Text] [Related]
17. Regional distribution of parkinsonism-preventing endogenous tetrahydroisoquinoline derivatives and an endogenous parkinsonism-preventing substance-synthesizing enzyme in monkey brain.
Yamakawa T; Kotake Y; Fujitani M; Shintani H; Makino Y; Ohta S
Neurosci Lett; 1999 Nov; 276(1):68-70. PubMed ID: 10586977
[TBL] [Abstract][Full Text] [Related]
18. Reduction of 1-methyl 1,2,3,4-tetrahydroisoquinoline level in substantia nigra of the aged rat.
Ayala A; Parrado J; Cano J; Machado A
Brain Res; 1994 Feb; 638(1-2):334-6. PubMed ID: 8199872
[TBL] [Abstract][Full Text] [Related]
19. Behavioral motor recovery in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned squirrel monkey (Saimiri sciureus): changes in striatal dopamine and expression of tyrosine hydroxylase and dopamine transporter proteins.
Petzinger GM; Fisher B; Hogg E; Abernathy A; Arevalo P; Nixon K; Jakowec MW
J Neurosci Res; 2006 Feb; 83(2):332-47. PubMed ID: 16385585
[TBL] [Abstract][Full Text] [Related]
20. Metabolism and penetration through blood-brain barrier of parkinsonism-related compounds. 1,2,3,4-Tetrahydroisoquinoline and 1-methyl-1,2,3,4-tetrahydroisoquinoline.
Kikuchi K; Nagatsu Y; Makino Y; Mashino T; Ohta S; Hirobe M
Drug Metab Dispos; 1991; 19(1):257-62. PubMed ID: 1673411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
